



PharmAust Launches New Corporate Website

29 November 2017 – Perth, Australia: PharmAust (ASX: PAA), a clinical-stage oncology company is pleased to announce the launch of its new corporate website.

The new website highlights the PharmAust's novel strategy of developing new targeted cancer therapies for both the human and animal healthcare markets.

The new website can accessed at www.pharmaust.com

Enquiries:

Dr Richard Hopkins
CEO
Tel: 0405 656 868
rhopkins@pharmaust.com

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
raston@pharmaust.com

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are support by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which is forecast to generate ~Aus\$4m in revenues in the 2018 FY

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial.